Know Cancer

or
forgot password

Lung Cancer Symptom Assessment and Management Intervention


Phase 2
21 Years
N/A
Open (Enrolling)
Both
Lung Cancer

Thank you

Trial Information

Lung Cancer Symptom Assessment and Management Intervention


Inclusion Criteria:



- HCPs: attending physician, thoracic medical oncologist, expected to work in the
setting for at least 2 years.

- Patients: 21 years of age or older; diagnosis of Stage IIIA, IIIB, IV non-small cell
lung cancer OR limited or extensive stage small cell lung cancer; receiving care in
the out-patient setting; receiving treatment with chemotherapy +/- additional
therapies; English speaking.

Exclusion Criteria:

- Patients: Any patient who needs emergent care, routine visits scheduled less than
once a month

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Outcome Measure:

% completion of intervention use and adherence to suggested symptom management strategies.

Outcome Time Frame:

2 years

Safety Issue:

No

Principal Investigator

Mary E. Cooley, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Dana-Farber Cancer Institute

Authority:

United States: Institutional Review Board

Study ID:

07-404

NCT ID:

NCT00852462

Start Date:

May 2008

Completion Date:

June 2013

Related Keywords:

  • Lung Cancer
  • SAMI
  • Symptom Assessment and Management Intervention Program
  • Lung Neoplasms

Name

Location
Dana-Farber Cancer Institute Boston, Massachusetts  02115
Boston Medical Center Boston, Massachusetts  02118